Gabriel Sayer, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1740405836
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 84.8% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $33,737, 3.6 times the $9,445 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 463 payments — averaging $204.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$80K
- Abiomed$4K
- Transmedics, Inc.$3K
- Medtronic$2K
- Ancora Heart, Inc.$1K
- One Lambda, Inc.$1K
- plus $4K from 28 others
Across 24 payments — averaging $2645.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$26K
- Abbott$19K
- Medtronic$16K
- Boehringer Ingelheim International GmbH$2K
- Novartis$101
What the payments were for
- Consulting fees$31,16933%
- Speaking & faculty fees$11,66912%
- Travel & lodging$24,72126%
- Food & beverage$27,13629%
- Education$180%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 289 | $80,340 |
| Abiomed | 22 | $3,596 |
| Transmedics, Inc. | 5 | $2,767 |
| Medtronic(2 entities) | 12 | $1,525 |
| Ancora Heart, Inc. | 4 | $1,200 |
| One Lambda, Inc. | 3 | $1,167 |
| Cvrx, Inc. | 7 | $838 |
| Novartis | 45 | $676 |
| Procyrion, Inc. | 4 | $325 |
| Opsens Inc. | 2 | $283 |
| Paragonix Technologies, Inc. | 1 | $248 |
| Merck | 12 | $237 |
| Boehringer Ingelheim | 10 | $197 |
| AstraZeneca | 8 | $166 |
| Itamar Medical Inc | 2 | $135 |
| Elutia, Inc. | 1 | $117 |
| Endotronix, Inc. | 1 | $108 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $105 |
| Alnylam Pharmaceuticals Inc. | 4 | $98 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $91 |
| Edwards Lifesciences | 1 | $76 |
| Bridgebio Pharma, Inc. | 2 | $59 |
| United Therapeutics Corporation | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Scpharmaceuticals Inc. | 1 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Vifor Pharma, Inc. | 1 | $33 |
| Amgen | 2 | $32 |
| Portola Pharmaceuticals, LLC | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Nihon Kohden America, LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$59,274
- HeartMate 3 Left Ventricular Dev$4,526
- Cardiovascular- Research only$3,600
- HeartMate 3 Left Ventricular Assist Device$2,900
- ORGAN CARE SYSTEM$2,767
- Impella$2,445
- CARDIOMEMS$2,033
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$1,317
- AccuCinch$1,200
- HeartWare HVAD$829
- Barostim Neo System$721
- CardioMEMS HF System$505
- HeartMate Touch$435
- OptoWire$283
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$265
- SherpaPak$248
- LIVERguard$248
- LUNGguard$248
- BaroGuard$248
- PancreasPak$248
How this compares
$94,730 in reported general payments places this provider in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $48,581 |
| EntrestoSacubitril/Valsartan | 45 | $48,402 |
| EliquisApixaban | 17 | $21,068 |
| FarxigaDapagliflozin Propanediol | 11 | $12,789 |
| Eplerenone | 14 | $786 |
| Torsemide | 16 | $597 |
| Metoprolol Succinate | 30 | $289 |
| Losartan Potassium | 33 | $260 |
| Spironolactone | 19 | $258 |
| Atorvastatin Calcium | 41 | $201 |
| Furosemide | 20 | $190 |
| Rosuvastatin Calcium | 23 | $187 |
| Amlodipine Besylate | 25 | $155 |
| Carvedilol | 12 | $145 |
| Prednisone | 12 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $197 | $48,58145 claims |
| NovartisEntresto | $676 | $48,40245 claims |
| PfizerEliquis | $12 | $21,06817 claims |
| AstraZenecaFarxiga | $166 | $12,78911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Johanna ContrerasNew York$534K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
- Kelly AxsomNew York$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.